PCSK9 and familial hyperaldosteronism: For instance, Scicali et al. demonstrated in 56 FH subjects that adding a PCSK9 inhibitor led to a comparable LDL-C reduction of 49.61% while also improving markers of inflammation and arterial stiffness (PWV) (56).